Patents by Inventor J. Keith Joung

J. Keith Joung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered CRISPR-Cas9 nucleases
    Patent number: 10093910
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 9, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Engineered CRISPR-Cas9 Nucleases with Altered PAM Specificity
    Publication number: 20180282714
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Application
    Filed: March 26, 2018
    Publication date: October 4, 2018
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Full Interrogation of Nuclease DSBs and Sequencing (FIND-seq)
    Publication number: 20180265920
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential off-target nuclease cleavage sites in DNA, e.g., in cell type-specific genomic DNA samples.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 20, 2018
    Inventors: J. Keith Joung, Shengdar Tsai
  • Comprehensive In vitro Reporting of Cleavage Events by Sequencing (CIRCLE-seq)
    Publication number: 20180245071
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential CRISPR-Cas9 off-target cleavage sites from cell type-specific genomic DNA samples.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 30, 2018
    Inventors: J. Keith Joung, Shengdar Tsai
  • METHODS FOR INCREASING EFFICIENCY OF NUCLEASE-INDUCED HOMOLOGY-DIRECTED REPAIR
    Publication number: 20180230494
    Abstract: The present invention relates to methods to improve the absolute rate of homology-directed repair (HDR) and/or to improve the relative rate of HDR compared with non-homologous end joining (NHEJ).
    Type: Application
    Filed: October 1, 2015
    Publication date: August 16, 2018
    Inventors: J. Keith JOUNG, Benjamin KLEINSTIVER, Jason Michael GEHRKE, Shengdar TSAI, James ANGSTMAN, Rebecca Tayler COTTMAN
  • Engineered CRISPR-Cas9 Nucleases
    Publication number: 20180216088
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Increasing Specificity for RNA-Guided Genome Editing
    Publication number: 20180208921
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: J. Keith Joung, James Angstman, Jeffry D. Sander, Morgan Maeder, Shengdar Tsai
  • TAL-Tet1 Fusion Proteins and Methods of Use Thereof
    Publication number: 20180187168
    Abstract: Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof.
    Type: Application
    Filed: February 12, 2018
    Publication date: July 5, 2018
    Inventors: J. Keith Joung, Morgan Maeder, James Angstman
  • Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
    Patent number: 10011850
    Abstract: Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided Foki Nucleases (RFNs), e.g., Fokl-Cas9 or Foki-dCas9-based fusion proteins.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: July 3, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Full interrogation of nuclease DSBs and sequencing (find-seq)
    Patent number: 9988674
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential off-target nuclease cleavage sites in DNA, e.g., in cell type-specific genomic DNA samples.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 5, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Engineered CRISPR-Cas9 nucleases with altered PAM specificity
    Patent number: 9944912
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 17, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Genomewide Unbiased Identification of DSBs Evaluated by Sequencing (GUIDE-Seq)
    Publication number: 20180087104
    Abstract: Unbiased, genomewide and highly sensitive methods for detecting mutations, e.g., off-target mutations, induced by engineered nucleases.
    Type: Application
    Filed: October 12, 2017
    Publication date: March 29, 2018
    Inventors: J. Keith Joung, Shengdar Tsai
  • Engineered CRISPR-Cas9 nucleases
    Patent number: 9926546
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: March 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Engineered CRISPR-CAS9 nucleases with altered PAM specificity
    Patent number: 9926545
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: March 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • SYNTHETIC TRANSCRIPTIONAL AND EPIGENETIC REGULATORS BASED ON ENGINEERED, ORTHOGONAL ZINC FINGER PROTEINS
    Publication number: 20180057838
    Abstract: Embodiments disclosed herein provide artificial expression systems comprising the zinc-finger containing transcription factors and engineered promoters to modulate expression of genes of interest. Engineered zinc-finger transcription factors that interact with engineered promoters constitute synthetic and regulatable expression systems which facilitate the modulation of gene expression as desired.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Ahmad S. Khalil, Divya Israni, Minhee Park, J. Keith Joung, Jeffry D. Sander
  • TAL-Tet1 fusion proteins and methods of use thereof
    Patent number: 9890364
    Abstract: Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 13, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Morgan Maeder, James Angstman
  • Increasing specificity for RNA-guided genome editing
    Patent number: 9885033
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 6, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, James Angstman, Jeffry D. Sander, Morgan Maeder, Shengdar Tsai
  • Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
    Publication number: 20180030425
    Abstract: Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.
    Type: Application
    Filed: July 25, 2017
    Publication date: February 1, 2018
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity
    Publication number: 20180002681
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Application
    Filed: March 3, 2016
    Publication date: January 4, 2018
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
    Patent number: 9850484
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential CRISPR-Cas9 off-target cleavage sites from cell type-specific genomic DNA samples.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 26, 2017
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai